Ocular complications following I-125 brachytherapy for choroidal melanoma

Eye

Volumn 23, Issue 6, 2009, Pages 1254-1268

  Wen, J C ^a   Oliver, S C ^b   McCannel, T A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JULES STEIN EYE INSTITUTE   (United States)

Author keywords

Brachytherapy; Choroidal melanoma; Complications; I 125; Review

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; BOTULINUM TOXIN A; CARBONATE DEHYDRATASE INHIBITOR; COBALT 60; CORTICOSTEROID; IODINE 125; LATANOPROST; LUBRICATING AGENT; MYDRIATIC AGENT; PALLADIUM 103; TRIAMCINOLONE;

BRACHYTHERAPY; BROWN SYNDROME; CHOROID MELANOMA; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DIPLOPIA; DISEASE COURSE; DRY EYE; EPISCLERAL DEPOSIT; EXTRACAPSULAR CATARACT EXTRACTION; EXTRAOCULAR MUSCLE; HUMAN; HYPERBARIC OXYGEN; IRIS NEOVASCULARIZATION; IRIS RUBEOSIS; KERATITIS; LASER COAGULATION; LENS IMPLANTATION; NEOVASCULAR GLAUCOMA; NEOVASCULARIZATION (PATHOLOGY); OPTIC NERVE DISEASE; PATHOGENESIS; PHACOEMULSIFICATION; RADIATION CATARACT; RADIATION INJURY; RADIATION RETINOPATHY; RETINA MACULOPATHY; RETINOPATHY; REVIEW; SCLERA DISEASE; SCLERA NECROSIS; STRABISMUS; VISUAL ACUITY; VITRECTOMY;

BRACHYTHERAPY; CHOROID NEOPLASMS; EYE DISEASES; HUMANS; IODINE RADIOISOTOPES; MELANOMA; VISUAL ACUITY;

EID: 67650660322     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2009.43     Document Type: Review

References (67)

1. Diener-West M, Earle JD, Fine SL, Hawkins BS, Moy CS, Reynolds SM et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol 2001; 119(7): 969-982.
2. Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol 2006; 124(12): 1684-1693.
3. Shields JA, Augsburger JJ, Brady LW, Day JL. Cobalt plaque therapy of posterior uveal melanomas. Ophthalmology 1982; 89(10): 1201-1207.
4. Finger PT, Moshfeghi DM, Ho TK. Palladium 103 ophthalmic plaque radiotherapy. Arch Ophthalmol 1991; 109(11): 1610-1613.
5. Packer S, Rotman M. Radiotherapy of choroidal melanoma with iodine 125. Int Ophthalmol Clin 1980; 20(2): 135-142.
6. Lommatzsch P. Treatment of choroidal melanomas with 106Ru/106Rh beta-ray applicators. Surv Ophthalmol 1974; 19(2): 85-100.
7. Heimann H, Coupland SE, Gochman R, Hellmich M, Foerster MH. Alterations in expression of mucin, tenascin-c and syndecan-1 in the conjunctiva following retinal surgery and plaque radiotherapy. Graefes Arch Clin Exp Ophthalmol 2001; 239(7): 488-495.
8. Durkin SR, Roos D, Higgs B, Casson RJ, Selva D. Ophthalmic and adnexal complications of radiotherapy. Acta Ophthalmol Scand 2007; 85(3): 240-250.
9. Quivey JM, Char DH, Phillips TL, Weaver KA, Castro JR, Kroll SM. High intensity 125-iodine (125I) plaque treatment of uveal melanoma. Int J Radiat Oncol Biol Phys 1993; 26(4): 613-618.
10. Lumbroso-Le Rouic L, Charif Chefchaouni M, Levy C, Plancher C, Dendale R, Asselain B et al. 125I plaque brachytherapy for anterior uveal melanomas. Eye 2004; 18(9): 911-916.
11. Finger PT. Radiation therapy for choroidal melanoma. Surv Ophthalmol 1997; 42(3): 215-232.
12. Puusaari I, Heikkonen J, Kivela T. Ocular complications after iodine brachytherapy for large uveal melanomas. Ophthalmology 2004; 111(9): 1768-1777.
13. Krohn J, Monge OR, Skorpen TN, Mørk SJ, Dahl O. Posterior uveal melanoma treated with I-125 brachytherapy or primary enucleation. Eye 2008; 22(11): 1398-1403.
14. Stack R, Elder M, Abdelaal A, Hidajat R, Clemett R et al. New Zealand experience of I125 brachytherapy for choroidal melanoma. Clin Experiment Ophthalmol 2005; 33(5): 490-494.
15. Detorakis ET, Engstrom Jr RE, Wallace R, Straatsma BR. Iris and anterior chamber angle neovascularization after iodine 125 brachytherapy for uveal melanoma. Ophthalmology 2005; 112(3): 505-510.
16. Bechrakis NE, Bornfeld N, Zoller I, Foerster MH. Iodine 125 plaque brachytherapy vs transscleral tumor resection in the treatment of large uveal melanomas. Ophthalmology 2002; 109(10): 1855-1861.
17. Fontanesi J, Meyer D, Xu S, Tai D. Treatment of choroidal melanoma with I-125 plaque. Int J Radiat Oncol Biol Phys 1993; 26(4): 619-623.
18. Mameghan H, Karolis C, Fisher R, Mameghan J, Billson FA, Donaldson EJ et al. Iodine-125 irradiation of choroidal melanoma: clinical experience from the Prince of Wales and Sydney Eye Hospitals. Australas Radiol 1992; 36(3): 249-252.
19. Bosworth JL, Packer S, Rotman M, Ho T, Finger PT. Choroidal melanoma: I-125 plaque therapy. Radiology 1988; 169(1): 249-251.
20. Garretson BR, Robertson DM, Earle JD. Choroidal melanoma treatment with iodine 125 brachytherapy. Arch Ophthalmol 1987; 105(10): 1394-1397.
21. Finger PT. Tumour location affects the incidence of cataract and retinopathy after ophthalmic plaque radiation therapy. Br J Ophthalmol 2000; 84(9): 1068-1070.
22. Char DH, Lonn LI, Margolis LW. Complications of cobalt plaque therapy of choroidal malanomas. Am J Ophthalmol 1977; 84(4): 536-541.
23. Hayreh SS. Neovascular glaucoma. Prog Retin Eye Res 2007; 26(5): 470-485.
24. Yanoff M, Duker JS, Augsburger JJ. Ophthalmology, 2nd edn. Mosby: St Louis, 2004.
25. Cogan DG, Donaldson DD, Reese AB. Clinical and pathological characteristics of radiation cataract. AMA Arch Ophthalmol 1952; 47(1): 55-70.
26. Ferrufino-Ponce ZK, Henderson BA. Radiotherapy and cataract formation. Semin Ophthalmol 2006; 21(3): 171-180.
27. Collaborative Ocular Melanoma Study Group. Incidence of cataract and outcomes after cataract surgery in the First 5 Years after iodine 125 brachytherapy in the Collaborative Ocular Melanoma Study COMS Report No. 27. Ophthalmology 2007; 117(7): 1363-1371.
28. Jensen AW, Petersen IA, Kline RW, Stafford SL, Schomberg PJ, Robertson DM. Radiation complications and tumor control after 125I plaque brachytherapy for ocular melanoma. Int J Radiat Oncol Biol Phys 2005; 63(1): 101-108.
29. Fish GE, Jost BF, Snyder WI, Fuller DG, Birch DG. Cataract extraction after brachytherapy for malignant melanoma of the choroid. Ophthalmology 1991; 98(5): 619-622.
30. Wachtlin J, Bechrakis NE, Schueler AO, Helbig H, Bornfeld N, Foerster MH. Phacoemulsification following treatment of choroidal melanoma. Graefes Arch Clin Exp Ophthalmol 2000; 238(12): 942-948.
31. Archer DB, Amoaku WM, Gardiner TA. Radiation retinopathy - clinical, histopathological, ultrastructural and experimental correlations. Eye 1991; 5( Pt 2): 239-251.
32. Archer DB, Gardiner TA. Ionizing radiation and the retina. Curr Opin Ophthalmol 1994; 5(3): 59-65.
33. Amoaku WM, Archer DB. Fluorescein angiographic features, natural course and treatment of radiation retinopathy. Eye 1990; 4(partt 5): 657-667.
34. Jones R, Gore E, Mieler W, Murray K, Gillin M, Albano K et al. Posttreatment visual acuity in patients treated with episcleral plaque therapy for choroidal melanomas: dose and dose rate effects. Int J Radiat Oncol Biol Phys 2002; 52(4): 989-995.
35. Sia S, Harper C, McAllister I, Perry A. Iodine-I25 episcleral plaque therapy in uveal melanoma. Clin Experiment Ophthalmol 2000; 28(6): 409-413.
36. Finger PT. Radiation retinopathy is treatable with anti-vascular endothelial growth factor bevacizumab (Avastin). Int J Radiat Oncol Biol Phys 2008; 70(4): 974-977.
37. Arriola-Villalobos P, Donate-Lopez J, Calvo-Gonzalez C, Reche-Frutos J, Alejandre-Alba N, Díaz-Valle D. Intravitreal bevacizumab (Avastin) for radiation retinopathy neovascularization. Acta Ophthalmol Scand 2008; 86(1): 115-116.
38. Ziemssen F, Voelker M, Altpeter E, Bartz-Schmidt KU, Gelisken F. Intravitreal bevacizumab treatment of radiation maculopathy due to brachytherapy in choroidal melanoma. Acta Ophthalmol Scand 2007; 85(5): 579-580.
39. Mason III JO, Albert Jr MA, Persaud TO, Vail RS. Intravitreal bevacizumab treatment for radiation macular edema after plaque radiotherapy for choroidal melanoma. Retina 2007; 27(7): 903-907.
40. Finger PT, Chin K. Anti-vascular endothelial growth factor bevacizumab (avastin) for radiation retinopathy. Arch Ophthalmol 2007; 125(6): 751-756.
41. Finger PT, Kurli M. Laser photocoagulation for radiation retinopathy after ophthalmic plaque radiation therapy. Br J Ophthalmol 2005; 89(6): 730-738.
42. Hykin PG, Shields CL, Shields JA, Arevalo JF. The efficacy of focal laser therapy in radiation-induced macular edema. Ophthalmology 1998; 105(8): 1425-1429.
43. Shields CL, Demirci H, Dai V, Marr BP, Mashayekhi A, Materin MA et al. Intravitreal triamcinolone acetonide for radiation maculopathy after plaque radiotherapy for choroidal melanoma. Retina 2005; 25(7): 868-874.
44. Gall N, Leiba H, Handzel R, Pe'er J. Severe radiation retinopathy and optic neuropathy after brachytherapy for choroidal melanoma, treated by hyperbaric oxygen. Eye 2007; 21(7): 1010-1012.
45. Gillies MC. Regulators of vascular permeability: potential sites for intervention in the treatment of macular edema. Doc Ophthalmol 1999; 97(3-4): 251-260.
46. Jermak CM, Dellacroce JT, Heffez J, Peyman GA. Triamcinolone acetonide in ocular therapeutics. Surv Ophthalmol 2007; 52(5): 503-522.
47. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, Miller JW, Haller JA, Reimann JD et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005; 112(6): 1048-1053.
48. Kinyoun JL, Zamber RW, Lawrence BS, Barlow WE, Arnold AM. Photocoagulation treatment for clinically significant radiation macular oedema. Br J Ophthalmol 1995; 79(2): 144-149.
49. Kinyoun JL, Chittum ME, Wells CG. Photocoagulation treatment of radiation retinopathy. Am J Ophthalmol 1988; 105(5): 470-478.
50. Levin LA, Gragoudas ES, Lessell S. Endothelial cell loss in irradiated optic nerves. Ophthalmology 2000; 107(2): 370-374.
51. Kline LB, Kim JY, Ceballos R. Radiation optic neuropathy. Ophthalmology 1985; 92(8): 1118-1126.
52. Miller NR. Radiation-induced optic neuropathy: still no treatment. Clin Experiment Ophthalmol 2004; 32(3): 233-235.
53. Danesh-Meyer HV. Radiation-induced optic neuropathy. J Clin Neurosci 2008; 15(2): 95-100.
54. Brown GC, Shields JA, Sanborn G, Augsburger JJ, Savino PJ, Schatz NJ. Radiation optic neuropathy. Ophthalmology 1982; 89(12): 1489-1493.
55. Shields CL, Demirci H, Marr BP, Mashayekhi A, Dai VV, Materin MA et al. Intravitreal triamcinolone acetonide for acute radiation papillopathy. Retina 2006; 26(5): 537-544.
56. Levy RL, Miller NR. Hyperbaric oxygen therapy for radiation-induced optic neuropathy. Ann Acad Med Singapore 2006; 35(3): 151-157.
57. Melia BM, Abramson DH, Albert DM, Boldt HC, Earle JD, Hanson WF et al. Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16. Ophthalmology 2001; 108(2): 348-366.
58. Brady LW, Hernandez JC. Brachytherapy of choroidal melanomas. Strahlenther Onkol 1992; 168(2): 61-65.
59. Toivonen P, Kivela T. Pigmented episcleral deposits after brachytherapy of uveal melanoma. Ophthalmology 2006; 113(5): 865-873.
60. Fukushima S, Inoue T, Inoue T, Ozeki S. Postoperative irradiation of pterygium with 90Sr eye applicator. Int J Radiat Oncol Biol Phys 1999; 43(3): 597-600.
61. MacKenzie FD, Hirst LW, Kynaston B, Bain C. Recurrence rate and complications after beta irradiation for pterygia. Ophthalmology 1991; 98(12): 1776-1780, discussion 1781).
62. Monteiro-Grillo I, Gaspar L, Monteiro-Grillo M, Pires F, Ribeiro da Silva JM. Postoperative irradiation of primary or recurrent pterygium: results and sequelae. Int J Radiat Oncol Biol Phys 2000; 48(3): 865-869.
63. Petrovich Z, McDonnell JM, Palmer D, Langholz BM, Liggett PE. Histopathologic changes following irradiation for uveal tract melanoma. Am J Clin Oncol 1994; 17(4): 298-306.
64. Earle J, Kline RW, Robertson DM. Selection of iodine 125 for the Collaborative Ocular Melanoma Study. Arch Ophthalmol 1987; 105(6): 763-764.
65. Kiratli H, Yilmaz PT, Sargon M. Ultrastructural alterations in extraocular muscles following iodine-125 brachytherapy for uveal melanoma. Strabismus 2007; 15(2): 103-109.
66. Sener EC, Kiratli H, Gedik S, Sanac AS. Ocular motility disturbances after episcleral plaque brachytherapy for uveal melanoma. J AAPOS 2004; 8(1): 38-45.
67. Dawson E, Sagoo MS, Mehta JS, Comer R, Hungerford J, Lee J et al. Strabismus in adults with uveal melanoma following episcleral plaque brachytherapy. J AAPOS 2007; 11(6): 584-588.